These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4006370)

  • 1. Antipyrine clearance in pneumonia.
    Sonne J; Døssing M; Loft S; Andreasen PB
    Clin Pharmacol Ther; 1985 Jun; 37(6):701-4. PubMed ID: 4006370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased values of antipyrine clearance in type IV hyperlipoproteinemia.
    Bedeleanu D; Trif I; Lötsch JC; Cucuianu MP
    Med Interne; 1986; 24(3):183-90. PubMed ID: 3775212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction.
    Hepner GW; Vesell ES
    Am J Dig Dis; 1975 Jan; 20(1):9-12. PubMed ID: 1115054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance.
    Elin RJ; Vesell ES; Wolff SM
    Clin Pharmacol Ther; 1975 Apr; 17(4):447-57. PubMed ID: 1122686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.
    Homeida M; Roberts CJ; Halliwell M; Read AE; Branch RA
    Gut; 1979 Jul; 20(7):596-601. PubMed ID: 488757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholestasis and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis.
    Miguet JP; Vuitton D; Deschamps JP; Allemand H; Joanne C; Bechtel P; Carayon P
    Dig Dis Sci; 1981 Aug; 26(8):718-22. PubMed ID: 7261836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver failure and drug metabolism.
    Andreasen PB; Ranek L
    Scand J Gastroenterol; 1975; 10(3):293-7. PubMed ID: 1138332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary disease and antipyrine clearance.
    Laybourn C; Tønnesen P; Loft S; Sonne J; Døssing M
    Clin Pharmacol Ther; 1986 Oct; 40(4):415-9. PubMed ID: 3489577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
    Hayes PC; Bouchier IA
    Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipyrin clearance in homozygous beta-thalassemia.
    Rifkind AB; Canale V; New MI
    Clin Pharmacol Ther; 1976 Oct; 20(4):476-83. PubMed ID: 975719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy.
    Relling MV; Crom WR; Pieper JA; Cupit GC; Rivera GK; Evans WE
    Clin Pharmacol Ther; 1987 Jun; 41(6):651-60. PubMed ID: 3472701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of prednisolone on antipyrine elimination in patients with obstructive lung disease.
    Loft S; Simonsen K; Evald T; Christensen HR; Sonne J; Døssing M
    Eur J Clin Pharmacol; 1987; 33(1):89-91. PubMed ID: 3691602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous administration of multiple model substrates to assess hepatic drug clearance.
    Crom WR; Webster SL; Bobo L; Teresi ME; Relling MV; Evans WE
    Clin Pharmacol Ther; 1987 Jun; 41(6):645-50. PubMed ID: 3581648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of combined therapy with cimetidine and (+)-cyanidanol-3 on the hepatic clearance of antipyrine].
    Adamska-Dyniewska I; Tkaczewski W; Jabłkowski M; Chojnacki J
    Pol Arch Med Wewn; 1986 Mar; 75(3):161-6. PubMed ID: 3763411
    [No Abstract]   [Full Text] [Related]  

  • 18. Accuracy and clinical utility of simplified tests of antipyrine metabolism.
    Farrell GC; Zaluzny L
    Br J Clin Pharmacol; 1984 Oct; 18(4):559-65. PubMed ID: 6487495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
    Soto Alvarez J; Alsar Ortiz MJ
    Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipyrine metabolism and bronchogenic carcinoma.
    Ambre J; Graeff D; Bures F; Haupt D; Deason K
    J Med; 1977; 8(1):57-70. PubMed ID: 267157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.